

NOTICES

Notice No.	20240909-65	Notice Date	09 Sep 2024
Category	Trading	Segment	Equity
Subject	Opening of Offer to Buy – Acquisition Window (Buyback) for AARTI DRUGS LIMITED		
Attachments	Aarti Drugs Limited_LOF.pdf		

Content

Trading Members and Custodians are requested to note that Securities Exchange Board of India (SEBI) has issued Mechanism for acquisition of shares through Stock Exchange pursuant to Tender-Offers under Takeover, Buy Back and De-listing vide its circular no. CIR/CFD/POLICYCELL/1/2015 dated April 13, 2015, and no. CFD/DCR2/CIR/P/2016/131 dated Dec 09, 2016. The Exchange vide its notice no. 20170210-16 dated Feb 10, 2017, 20190424-35 dated April 24, 2019, and 20200528-32 dated 28 May 2020, 20201102-43 dated Nov 02, 2020, and 20210825-62 dated Aug 25, 2021 has issued Revised Guidelines of Mechanism for acquisition of shares through Stock Exchange pursuant to Tender-Offers under Takeovers, Buy Back and Delisting.

All Market Participants are hereby informed that **AARTI DRUGS LIMITED** ("The Company") has announced an Offer to Buyback up to **6,65,000 (Six Lakhs Sixty-Five Thousand)** fully paid-up equity shares of the company of face value of Rs.10/- (Rupees Ten Only) each ("equity shares"), representing up to 0.72% of the total number of issued, subscribed and paid up equity shares of the company, from all the equity shareholders/beneficial owners of the company who holds equity shares as on the record date i.e. Thursday, September 5, 2024 ("Record Date"), on a proportionate basis, through the tender offer using stock exchange mechanism ("tender offer"), at a price of Rs. 900/- (Rupees Nine Hundred Only) per equity share ("Buyback price") payable in cash for an aggregate amount of up to Rs. 59,85,00,000/- (Rupees Fifty-Nine Crores Eighty-Five Lakhs Only) ("Buyback size") excluding the transaction cost (as defined below) ("Buyback"), **From Wednesday, September 11, 2024, to Wednesday, September 18, 2024 (Excluding September 16, 2024 due to SEBI holiday)**

Letter of Offer is herewith attached for perusal.

Market participants are further requested to note that this offer will be as per the SEBI circular no. CIR/CFD/POLICYCELL/1/2015 dated April 13, 2015 and SEBI circular no. CFD/DCR2/CIR/P/2016/131 dated Dec 09, 2016 and Exchange notice no. 20170210-16 dated Feb 10, 2017, 20190424-35 dated April 24, 2019 and 20200528-32 dated 28 May 2020 and the details of this Offer to Buy would be available on BSE Website – www.bseindia.com.

Mangesh Tayde
Deputy General Manager
Listing Business Relationship
September 09, 2024